201 related articles for article (PubMed ID: 24100628)
1. Targeting SRC and tubulin in mucinous ovarian carcinoma.
Liu T; Hu W; Dalton HJ; Choi HJ; Huang J; Kang Y; Pradeep S; Miyake T; Song JH; Wen Y; Lu C; Pecot CV; Bottsford-Miller J; Zand B; Jennings NB; Ivan C; Gallick GE; Baggerly KA; Hangauer DG; Coleman RL; Frumovitz M; Sood AK
Clin Cancer Res; 2013 Dec; 19(23):6532-43. PubMed ID: 24100628
[TBL] [Abstract][Full Text] [Related]
2. Targeting SRC in mucinous ovarian carcinoma.
Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
[TBL] [Abstract][Full Text] [Related]
3. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.
Kim S; Min A; Lee KH; Yang Y; Kim TY; Lim JM; Park SJ; Nam HJ; Kim JE; Song SH; Han SW; Oh DY; Kim JH; Kim TY; Hangauer D; Lau JY; Im K; Lee DS; Bang YJ; Im SA
Cancer Res Treat; 2017 Jul; 49(3):643-655. PubMed ID: 27737538
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.
Sato S; Itamochi H; Kigawa J; Oishi T; Shimada M; Sato S; Naniwa J; Uegaki K; Nonaka M; Terakawa N
Cancer Sci; 2009 Mar; 100(3):546-51. PubMed ID: 19154404
[TBL] [Abstract][Full Text] [Related]
6. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
[TBL] [Abstract][Full Text] [Related]
7. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.
Sato N; Saga Y; Mizukami H; Wang D; Fujiwara H; Takei Y; Machida S; Ozawa K; Suzuki M
Oncol Rep; 2012 May; 27(5):1336-40. PubMed ID: 22246397
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure.
Wang L; Zheng Y; Li D; Yang J; Lei L; Yan W; Zheng W; Tang M; Shi M; Zhang R; Cai X; Ni H; Ma X; Li N; Hong F; Ye H; Chen L
J Med Chem; 2021 Jun; 64(12):8127-8141. PubMed ID: 34081857
[TBL] [Abstract][Full Text] [Related]
10. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
11. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
13. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin.
Gao F; Liang Y; Zhou P; Cheng J; Ding K; Wang Y
Eur J Med Chem; 2019 Sep; 178():177-194. PubMed ID: 31185410
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
17. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
